Citadel Advisors’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-51,200
| Closed | -$42.2K | – | 13911 |
|
|
2025
Q1 | $42.2K | Buy |
51,200
+41,200
| +412% | +$39.7K | ﹤0.01% | 12483 |
|
|
2024
Q4 | $9.5K | Buy |
10,000
+700
| +8% | +$660 | ﹤0.01% | 13645 |
|
|
2024
Q3 | $9.3K | Sell |
9,300
-22,100
| -70% | -$24.5K | ﹤0.01% | 13265 |
|
|
2024
Q2 | $38.9K | Buy |
31,400
+26,600
| +554% | +$27.1K | ﹤0.01% | 12021 |
|
|
2024
Q1 | $6.24K | Buy |
+4,800
| New | +$5.47K | ﹤0.01% | 13693 |
|
|
2023
Q2 | – | Sell |
-10,500
| Closed | -$15.3K | – | 14828 |
|
|
2023
Q1 | $15.3K | Buy |
10,500
+10,100
| +2,525% | +$19.4K | ﹤0.01% | 13259 |
|
|
2022
Q4 | $648 | Buy |
+400
| New | +$921 | ﹤0.01% | 14608 |
|
|
2022
Q3 | – | Sell |
-52,200
| Closed | -$190K | – | 13149 |
|
|
2022
Q2 | $190K | Buy |
52,200
+800
| +2% | +$3.63K | ﹤0.01% | 10750 |
|
|
2022
Q1 | $372K | Buy |
+51,400
| New | +$438K | ﹤0.01% | 10094 |
|
Citadel Advisors's KRON Position: Q1 2025 in Review
Citadel Advisors sold out of Kronos Bio (KRON) in Q1 2025, closing a stake of 186,711 shares — an estimated $180K sold.
Citadel Advisors first reported a position in KRON in Q4 2020 and held it in 17 quarters. The position peaked at $27.9M in Q4 2020. 47 funds tracked by Wall St. Rank hold KRON as of Q1 2025.
- Citadel Advisors reported no remaining Kronos Bio position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 186,711 Kronos Bio shares in Q1 2025, an estimated $180K.
- Citadel Advisors first reported a position in Kronos Bio in Q4 2020 and held it in 17 quarters.
- Citadel Advisors's Kronos Bio position peaked at $27.9M in Q4 2020.
- 47 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.